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Comparative Effectiveness of Total Population versus
Disease-Specific Neural Network Models in
Predicting Medical Costs
ALBERT G. CRAWFORD, Ph.D., M.B.A., M.S.I.S.,1 JOSEPH P. FUHR, JR., Ph.D.,1
JANICE CLARKE, R.N., B.B.A.,1 and BRANDON HUBBS, M.A.2

ABSTRACT
The objective of this research was to compare the accuracy of two types of neural networks
in identifying individuals at risk for high medical costs for three chronic conditions. Two
neural network models—a population model and three disease-specific models—were compared regarding effectiveness predicting high costs. Subjects included 33,908 health plan
members with diabetes, 19,264 with asthma, and 2,605 with cardiac conditions. For model development/testing, only members with 24 months of continuous enrollment were included.
Models were developed to predict probability of high costs in 2000 (top 15% of distribution)
based on 1999 claims factors. After validation, models were applied to 2000 claims factors to
predict probability of high 2001 costs. Each member received two scores—population model
score applied to cohort and disease model score. Receiver Operating Characteristic (ROC)
curves compared sensitivity, specificity, and total performance of population model and three
disease models. Diabetes-specific model accuracy, C  0.786 (95%CI  0.779–0.794), was
greater than that of population model applied to diabetic cohort, C  0.767 (0.759–0.775).
Asthma-specific model accuracy, C  0.835 (0.825–0.844), was no different from that of population model applied to asthma cohort, C  0.844 (0.835–0.853). Cardiac-specific model accuracy, C  0.651 (0.620–0.683), was lower than that of population model applied to cardiac cohort, C  0.726 (0.697–0.756). The population model predictive power, compared to the disease
model predictive power, varied by disease; in general, the larger the cohort, the greater the
advantage in predictive power of the disease model compared to the population model. Given
these findings, disease management program staff should test multiple approaches before implementing predictive models. (Disease Management 2005;8:277–287)

INTRODUCTION

R

one half of all health care costs in
the United States stem from chronic diseases, and this proportion is expected to increase as the proportion of seniors rises.1 By the
OUGHLY
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year 2020, it is expected that approximately
50% of Americans (157 million) will have one
or more chronic illnesses.2 Each of the three
chronic conditions included in this study generates more than $10 billion annually in U.S.
healthcare costs:
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• Diabetes generated $132 billion in direct and
indirect costs in 2002.
• Asthma generated $12.7 billion in healthcare
costs in 1998.
• Heart failure generated $22 billion in direct
costs in 2003.3
Over the past decade, disease management
(DM) programs have proven effective in controlling these costs while improving health outcomes.4 DM is a process by which health plan
members at risk of chronic illness are identified
and targeted for interventions aimed at improving their clinical outcomes, thereby reducing medical costs associated with poorly controlled conditions.5 A core component of DM
is identification of individuals at risk of development or exacerbation of illness and concomitant costs.5–10 Using various disease markers, types of health services utilization, and
healthcare cost levels, predictive modeling
techniques have been developed to pinpoint individuals at risk for adverse health outcomes.
Predictive models can be either generic or specific in their population of interest. Another
dimension of differentiation among predictive
models is the specific analytical technique employed, eg, linear or logistic regression analyses, classification/decision trees, or neural networks.11–13
Neural network techniques are derived from
theories of human cognition and employ nonstatistical algorithms to explain or predict variations in data. In neural networks, the individual inputs to a neuron, with initial values of 0
or 1, are multiplied by their respective weights,
and these weighted inputs are summed and
processed through a threshold function to determine whether the summed input exceeds the
threshold for the neuron.
There are various types of neural networks,
based on number of neurons, number of layers, number of hidden layers, and number of
outputs. The most common implementation
of neural networks is backpropagation. Backpropagation is a two-stage process, consisting
of (1) feed-forward activation from the input
layer to the output layer, and (2) propagation
of errors and adjustments backward to the input layer. In backpropagation, if an output is
correct, no change is necessary; if there is a false
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positive or false negative error, each weight is
adjusted according to the direction and degree
of error. Backpropagation requires hidden layers, ie, middle layers that provide an internal
model of how inputs are related to outputs. As
the number of hidden layers increases, the
training error rate decreases as a result of increased flexibility in modeling the data.
Applications of neural networks include
games, speech synthesis and interpretation,
and signal processing, cleaning, and interpretation, as well as the focus of this analysis, medical decision-making, specifically diagnosis.
Neural networks have recently been used to
predict, among other outcomes, acute pancreatitis patient outcomes,14 length of stay in a
postanesthesia care unit,15 breast cancer survival,16 and 5-year colon carcinoma survival.13
One important issue is how neural network
techniques compare in predictive power with
statistical techniques, ie, linear and logistic regression. The four studies cited immediately
above all compared neural network analyses
with other analytic techniques. In the study
predicting acute pancreatitis patient outcomes
by Keogan et al,14 neural network predictions
were not significantly better than linear discriminant analysis predictions (C  0.83 and
C  0.82, respectively). On the other hand, in
the study of postanesthesia care unit length of
stay by Kim et al,15 a neural network predicted
correctly in 81.4% of situations, while logistic
regression analysis predicted correctly in
65.0%. Similarly, the study of breast cancer survival by Burke et al16 found that both a backpropagation neural network (C  0.768) and a
probabilistic neural network (C  0.759) were
significantly more accurate than the pTNM
(primary tumor, regional lymph nodes, and
distant metastases) staging system in predicting breast cancer survival (C  0.720). Finally,
the comparison by Snow et al13 predicting 5year colon carcinoma survival found that a
neural network performed better than a standard parametric logistic regression in terms of
both C-statistics and specificities at 95% sensitivity.
Among the reasons why neural networks often perform better than statistical techniques
are the assumptions required by the latter.
Clinical research must address numerous di-
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chotomous outcomes, including health versus
illness, receiving a service or not, being admitted to a hospital or not, and survival itself.
While linear regression cannot handle dichotomous outcomes, logistic regression can do so.
Still, no regression technique has the capability
to handle associations between outcomes, continuous or dichotomous, and predictor variables whose effects are neither simply linear
nor linear following adjustment through a
mathematical transformation, eg, logarithmic/exponential, polynomial, trigonometric.
In contrast, neural networks have no such limitations in terms of either forms of variables or
forms of associations between variables. While
neural networks have the aforementioned
strengths in incorporating complex variables
and associations and in overall predictive
power, they also have weaknesses. Among
their disadvantages are use of hidden layers
(which are inherently somewhat indescribable), lack of easily interpretable results, and,
specifically, lack of detailed or summary quantitative results.17,18
The general aim of this analysis was to compare the effectiveness of two neural network
modeling approaches in predicting high medical costs: a model based on a population of
health plan members versus three cohort models targeting members with specific diseases, ie,
asthma, diabetes, and cardiac conditions—congestive heart failure (CHF) and coronary artery
disease (CAD). A more specific aim of the analysis was to determine the more effective prediction method to increase the clinical benefits
and cost effectiveness of the DM program.
The conditions studied—diabetes, asthma,
and CHF and CAD combined—were selected
because they are the three conditions most
commonly targeted by DM programs. Of all
health plans participating in the 2001 American Association of Health Plans Annual Industry Survey, 97% had a diabetes DM program, 86% had an asthma DM program, and
83% had a CHF DM program.19
The total population model was developed
through analysis of a health plan population
containing members with and without chronic
diseases. Each disease-specific model was developed by focusing on the cohort of members
diagnosed with or having risk factors for that
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disease. The choice of the outcome of high future costs was driven by two exigencies: (1) the
availability and importance of high costs as an
indicator of adverse health status, and (2) the
goal of managing the DM program as cost effectively as possible.

MATERIALS AND METHODS
The total study population consisted of
375,426 members of a health plan where American Healthways, Inc. provided DM services.
The three disease cohorts included 33,908
members with diabetes, 19,264 members with
asthma, and 2,605 members with CHF and/or
CAD. A caveat is in order regarding the disease hierarchies in the three cohorts. On the one
hand, the asthma cohort is relatively uniform:
only 0.8% of its members have cardiac conditions and only 0.3% have diabetes; moreover,
since there is a separate chronic obstructive
pulmonary disease (COPD) cohort not included in these analyses, there are no members
with COPD in the asthma cohort. On the other
hand, the diabetes and cardiac cohorts are more
complex: in the diabetes cohort, 18.2% have cardiac conditions and 9.6% have asthma; and, in
the cardiac cohort, 5.6% have diabetes and
11.3% have asthma.
The time frame of the study was calendar
years 1999–2001, where 1999 was modeling
year 1, 2000 was modeling year 2, and 2001 was
the evaluation year.
The outcome variable predicted by the models was high medical costs, defined as the top
15% of the total cost distribution, ie, the segment targeted for the most intense disease
management interventions. This kind of operational definition of high costs reflects the fact
that approximately 10% of the US population
is responsible for roughly 70% of direct medical costs.20 A set of potential predictive risk
factors was identified for use in modeling both
the total population and each of the three disease cohorts. American Healthways, Inc. collected and processed all relevant medical
(inpatient, outpatient, and physician) and pharmacy claims, laboratory results, and other clinical data to identify risk factors and to develop,
calibrate, and implement the predictive mod-
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els for this member population. In model development, a set of more than 100 risk factors
was compiled based on (1) epidemiological and
clinical knowledge of chronic disease conditions and their progression, and (2) the clinical
and administrative experience of a wide range
of commercial health plans.
Proprietary algorithms employed a variety
of factors derived from members’ claims histories to identify members with each chronic condition. A specific identification algorithm was
developed for each disease, including data
drawn from both medical claims—International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) diagnosis
codes, ICD-9 procedure codes, and Current
Procedure Terminology (CPT) procedure
codes—and pharmacy claims—National Drug
Code (NDC) codes. Selection criteria for diabetes and for asthma included a combination
of specific ICD-9 and NDC codes; selection criteria for cardiac conditions included a combination of specific ICD-9, CPT, and NDC codes.
Given that the identification of each disease cohort required at least two services with specified ICD-9 diagnosis codes, the false positive
rate for each disease cohort is less than 5%, suggesting that false positives do not represent a
major limitation of these analyses.
Decision trees were used to reduce the total
set of more than 100 predictive factors to
smaller subsets of factors based on their relationships to the outcome variable, high medical costs. The threshold to include a factor in
each subset was a chi-square significance test
where p  0.20. Each of the four neural network models contained one hidden layer, and
within this layer a default value of three hidden units was used. The average error model
selection criterion was used for each neural
network. All classification and neural network
modeling was performed using SAS Enterprise Miner,® version 4.1.21 The ultimate criterion for inclusion in the model was that the
importance statistic, representing the relative
importance of a variable and generated by the
decision tree component of SAS Enterprise
Miner, had a value greater than or equal to
0.05.21
Four metrics by which a predictive model
can be evaluated are (1) the true positive rate
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(sensitivity), (2) the true negative rate (specificity), (3) the false positive rate, and (4) the
false negative rate. These rates are interrelated.
The false positive rate represents the percentage of members who were predicted to incur
high costs but who did not actually incur high
costs. The false negative rate represents the percentage of members who were not predicted to
incur high costs but who actually incurred high
costs.
Receiver Operating Characteristic (ROC)
curves were plotted to compare the performance of the total population model with that
of each disease-specific model. These ROC
curves plot the sensitivity of each model as a
function of its false positive rate (1 minus specificity); the area under the ROC curve represents
the overall accuracy or performance of each
model.22,23 The three comparisons focused on
differences between the confidence intervals
around the pairs of C-statistics generated by
applying the two predictive models (total population and disease specific) to each disease cohort. The C-statistic can range from 0 to 1; a
C-statistic of 0.50 would indicate that a model
was 50% accurate in categorizing members as
having high versus low costs (odds which are
no greater than chance); a C-statistic of 1.00
would indicate a perfect model, ie, a model that
perfectly predicts whether members incur high
cost or not.
The four neural network models were constructed using claims data for modeling year 1
(1999) to predict which members had high costs
in modeling year 2 (2000). After the models
were developed and validated, they were applied to modeling year 2 (2000) claims factors
to predict year 3 (2001) costs. The outcome of
interest is the probability that members have
high costs in year 3. Members in each of the
three disease categories received two scores,
one based on the total population model applied to the disease cohort and the other based
on the respective disease-specific model. True
positive high cost members were identified as
those in the top 15% of the year 3 cost distribution.
The choice of a dichotomous outcome rather
than a continuous one was guided by comparative analysis of models with the two forms of
outcomes. One population model was fitted to
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a dichotomous target, and another population
model was fitted to a continuous, ie, interval
scale target. Two sets of scores were assigned
to the population, and model performance was
compared at the 15% screening level. The results were consistent with those derived from
analyses of data from other health plans: dichotomous targets consistently perform better
than continuous targets, with a significantly
higher percentage of high cost members captured at the 15% screening threshold, 56.25%
versus 54.19%.
Sensitivity analyses were performed using
different predictive modeling scenarios, varying the target percentages defining members’
high medical costs, ie, 1%, 5%, 10%, 15%, 20%,
and 30%. These analyses allowed for an assessment of any variations in the accuracy of
the models depending on the threshold selected.

RESULTS
Total population model
The total population model (Table 1) includes the following predictive factors, listed in
descending order according to the magnitude
of their importance statistics: total medical
costs, physician costs, prescription drug costs,
number of unique diagnoses, age, number of
prescription drug claims, number of unique
procedures, hypertension symptoms, CAD
symptoms, inpatient costs, and diabetes symptoms. Four of the 11 factors in the total population model indicate costs, another three are
symptoms, three indicate intensity/complexity
of utilization, and the remaining factor is age.
Disease-specific models
Diabetes. The diabetes model includes the following predictive factors, shown in descending

TABLE 1. IMPORTANCE STATISTICS FOR PREDICTIVE FACTORS IN TOTAL
POPULATION MODEL AND THREE DISEASE-SPECIFIC MODELS
Factor

Population

Diabetes

Diabetes symptoms
Hypertension symptoms
Coronary artery disease symptoms
Asthma symptoms
COPD symptoms
Cancer symptoms
Osteoarthritis symptoms
End stage renal disease symptoms
IBD symptoms

0.0652
0.2786
0.1283

0.3885

Age

0.5066

0.2965

0.6055

0.7193

Total medical costs
Inpatient costs
Outpatient costs
Physician costs
Prescription drug costs

1.0000
0.1029

1.0000

1.0000

0.4799
0.9134
0.4509

0.4774
0.8925
0.4275

0.9387
0.2112
0.5133
1.0000

0.4277

0.1719
0.3477

0.3526
0.2775
0.3537
0.2936

0.4014
0.6834
0.3971

Number
Number
Number
Number
Number
Number
Number

of
of
of
of
of
of
of

hospitalizations
specialist visits
emergency room visits
prescription drug claims
unique diagnosis codes
procedure codes
unique procedure codes

Asthma

0.4201

Cardiac

0.4095
0.4149
0.6126
0.6809
0.1592
0.1104

0.0743
0.2113

0.9509
0.5305

0.4930
0.4949
0.5119
0.4754

COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease.

0.6710
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order according to their importance statistics:
total medical costs, physician costs, outpatient
costs, prescription drug costs, number of hospitalizations, diabetes symptoms, number of
procedures, number of prescription drug
claims, age, number of unique procedures,
number of unique diagnoses, and end stage renal disease symptoms. In the diabetes model,
four of the 12 factors indicate costs, only two
are symptoms (one being diabetes itself), five
indicate intensity/complexity of utilization,
and the remaining factor is age.
Asthma. The asthma model includes the following predictive factors, listed in descending
order of importance: total medical costs, physician costs, number of unique diagnoses, age,
outpatient costs, prescription drug costs,
asthma symptoms, number of prescription
drug claims, number of procedures, number of
specialist visits, and number of hospitalizations. In the asthma model, four of the 11 factors indicate costs, only one (asthma) is a symptom factor, five indicate intensity/complexity
of utilization, and the remaining factor is age.
Cardiac. The cardiac model includes the following predictive factors, listed in descending
order of importance: physician costs, total medical costs, age, chronic obstructive pulmonary
disease symptoms, number of procedures,
asthma symptoms, outpatient costs, number of
emergency room visits, CAD symptoms, hypertension symptoms, inflammatory bowel disease
symptoms, inpatient costs, cancer symptoms,
and osteoarthritis symptoms. In the cardiac
model, four of the 14 factors indicate costs, seven
are symptoms, two indicate intensity/complexity of utilization, and the remaining factor is age.
TABLE 2.

Comparison of total population model with
disease-specific models. To compare the effectiveness of the total population model with that
of the three disease-specific models, two ROC
curves were plotted for each disease. These
ROC curves plot the sensitivity of each model
versus its false positive rate (1 minus specificity). The area under each curve represents
the overall accuracy of that model and is evaluated by the C-statistic. The 95% confidence interval of the C-statistic for each application of
the population model is compared with the
confidence interval of the C-statistic for the respective disease model. The results are shown
in Table 2.
The accuracy of the diabetes model at the
95% confidence level, C  0.786 (CI  0.779–
0.794) was significantly higher than that of the
total population model applied to the diabetic
cohort, C  0.767 (CI  0.759–0.775). The accuracy of the asthma model, C  0.835 (CI 
0.825–0.844), was not significantly different
from that of the total population model applied
to the asthmatic cohort, C  0.844 (CI 
0.835–0.853). In contrast, the accuracy of the
cardiac model, C  0.651 (CI  0.620–0.683),
was significantly lower than that of the total
population model applied to the cardiac cohort,
C  0.726 (CI  0.697–0.756).
The analyses reported above used the 15%
screening threshold, ie, prospectively identifying the top 15% of members in terms of medical costs in the following year. A more finegrained analysis of the performance of the
models at this screening threshold shows that:
for persons with diabetes, the total population
model (sensitivity  0.422, specificity  0.898)
performed worse than the diabetes model (sensitivity  0.475, specificity  0.907), paralleling

MODEL PERFORMANCE COMPARISON: POPULATION MODEL

VERSUS

DISEASE MODELS

Population model accuracy,
C, 95% CI

Disease-specific model accuracy,
C, 95% CI

Diabetes
(n  33,908)

C  0.767
CI  0.579–0.775

C  0.786
CI  0.779–0.794

Asthma
(n  19,264)

C  0.844
CI  0.835–0.853

C  0.835
CI  0.825–0.844

Cardiac
(n  2,605)

C  0.726
CI  0.697–0.756

C  0.651
CI  0.620–0.683

Disease

283

COMPARATIVE EFFECTIVENESS OF NEURAL NETWORK MODELS

members were defined as having high medical
costs was varied from 1% up to 30%. These
comprehensive sensitivity analyses demonstrate the consistency of the patterns reported
above, regardless of the threshold percentage
selected. The diabetes-specific model is superior to the population model throughout the
entire range of screening thresholds. Its advantage in both sensitivity and specificity increases between the 1% and 10% thresholds,
plateaus between 10% and 20%, and diminishes somewhat between 20% and 30%, but its
superiority is still substantial at the 30% threshold; the diabetes model advantage in sensitivity always exceeds 0.03, and its advantage in
specificity always exceeds 0.006. The close similarity between the population model and the
asthma-specific model persists across the range
of screening thresholds; while there is some
fluctuation in the difference in sensitivity, that

the results reported above based on C-statistics; for persons with asthma, the total population model (sensitivity  0.535, specificity 
0.918) and the asthma model (sensitivity 
0.530, specificity  0.917) were virtually identical, paralleling the C-statistic analyses; and,
for cardiac patients the total population model
(sensitivity  0.361, specificity  0.888) performed better than the cardiac model (sensitivity  0.302, specificity  0.877), once again
in accordance with the C-statistic analyses.
To summarize, comparing model performance based on the C-statistic demonstrated
that the diabetes model performed better than
the total population model, the asthma model
approximated the total population model in
performance, and the cardiac model performed
worse than the total population model.
Table 3 shows the results of sensitivity analyses where the threshold percentage at which

TABLE 3.

SENSITIVITY/SPECIFICITY COMPARISON: POPULATION MODEL
DISEASE MODELS, BY SCREENING THRESHOLD

VERSUS

Total population
Screening threshold
0.01
0.05
0.10
0.15
0.20
0.30

Diabetes specific

Sensitivity

Specificity

Sensitivity

Specificity

0.059
0.203
0.323
0.422
0.502
0.636

0.999
0.977
0.939
0.898
0.853
0.759

0.059
0.234
0.374
0.475
0.552
0.669

0.999
0.983
0.948
0.907
0.862
0.765

Total population
Screening threshold
0.01
0.05
0.10
0.15
0.20
0.30

Asthma specific

Sensitivity

Specificity

Sensitivity

Specificity

0.064
0.256
0.416
0.535
0.623
0.744

1.000
0.986
0.956
0.918
0.875
0.778

0.060
0.260
0.420
0.530
0.611
0.736

0.999
0.987
0.956
0.917
0.873
0.777

Total population
Screening threshold
0.01
0.05
0.10
0.15
0.20
0.30

Cardiac specific

Sensitivity

Specificity

Sensitivity

Specificity

0.038
0.169
0.269
0.361
0.427
0.568

0.995
0.971
0.930
0.888
0.840
0.748

0.046
0.153
0.233
0.302
0.358
0.463

0.996
0.968
0.924
0.877
0.828
0.729
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difference never exceeds 0.012; and the difference in specificity never exceeds 0.002. On the
other hand, the disadvantage of the cardiac
model compared to the population model, particularly in sensitivity, becomes progressively
greater as the threshold increases: the cardiac
model disadvantage in sensitivity increases to
a maximum of 0.105 at the 30% threshold, and
its disadvantage in specificity increases to a
maximum of 0.019 at the 30% threshold. Given
all of these sensitivity analysis findings, it is
reasonable to conclude that the findings based
on the 15% screening threshold are not an artifact of the threshold choice but are generalizable to a wide range of plausible thresholds.

DISCUSSION
The primary aim of this study was to compare the relative accuracy, or effectiveness, of
a total population neural network model with
each of three disease-specific neural network
models in predicting which health plan members will incur high costs. The working hypothesis was that the disease-specific models
would outperform the total population model.
The most striking finding is that of the variable effectiveness of the disease models. When
the disease models were compared with the
total population model, the diabetes model
was more effective than the total population
model applied to persons with diabetes, the
asthma model was roughly equivalent, and
the cardiac model was less effective than the
total population model applied to the cardiac
cohort. If these results are substantiated by
further analyses, they may imply that the
choice of approach should be treated as an empirical question to be answered specifically for
each disease.
Evaluating these results in light of the DM,
predictive modeling, and medical informatics
literature is difficult, given little comparable
evidence. C-statistics reported in the literature
have generally ranged from 0.5 to 0.9. However, valid comparisons of C-statistics require
greater similarities in designs and data than can
be found in the few published studies. Further
research employing more standardized designs
is needed to address these issues.

Still, it is noteworthy that the sets of significant predictive factors identified in each of the
four models are very similar to those identified
in the literature. Typically, prior costs are
highly effective predictors of future costs; cost
factors taken collectively—including total medical costs, factors which decompose total costs
into components (eg, inpatient costs), and
changes over time in these factors—represent
the most common class of predictors. Intensity/complexity of utilization factors (eg, number of hospitalizations, specialist visits, emergency room visits) and changes therein
represent the second most common class of
predictors. Symptom factors taken together
represent a smaller but important source of
predictors, ranging from five symptoms in the
total population model to a diagnosis of asthma
alone in the asthma model. Finally, age stands
alone among the demographic factors as an effective predictor. Its generality of effectiveness
is impressive: it has the third highest importance statistic in the asthma and cardiac models, the fifth highest in the total population
model, and the ninth highest in the diabetes
model.
Looking at the effectiveness of the predictive
factors in a more granular way, total medical
costs in the prior year was generally the most
powerful predictor of high costs; total medical
costs had the highest importance in all but the
cardiac model, where it had the second highest importance. Total physician cost was the
second most powerful predictor in the four
models; it had the highest importance in the
cardiac model and the second highest importance in the other three models. The third most
powerful predictor was age; it was the only
powerful demographic predictor, as noted
above, and had high importance in all four
models.
Five other factors were important predictors
in three out of the four models: outpatient costs,
prescription drug costs, number of prescription drug claims, number of unique diagnosis
codes, and number of procedure codes.
The matrix of effects of symptoms on costs
is relatively sparse in that no symptom factor
has a high importance rating in more than
two of the models, and many of the symptom
factors with the highest importance statistics
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are somewhat tautological. Hypertension and
coronary artery disease are highly important
factors predicting high medical costs in the
cardiac model. Similarly, diabetes symptoms
are highly important in predicting high costs
in the diabetic cohort. The fact that asthma
symptoms is the only symptom factor predicting high medical costs among persons
with asthma highlights the absence of other
symptom factors. At the same time, all of
these symptom factors except asthma—hypertension, CAD, and diabetes—have high
importance ratings in the total population
model.
There are some parallels between the results
in this study and the results in the literature. A
study by Dove et al.8 sought to identify highrisk members in a subpopulation of managed
care organization members with previously
low medical costs, employing techniques similar to those reported herein (ie, multiple regression analysis, a comparative study design,
and an ROC curve). Dove et al.7 reported the
area under the curve to be 0.73, and found predictors similar to those in the analyses presented herein: diabetes, cardiac, respiratory,
and psychiatric conditions (based on medications and diagnoses), “nonhospital, non-emergency department, nonphysician medical claim
variable,” “composite prescription claim variable: measure of prescription drug classes,”
and symptoms/comorbidities (truncated at
four).
Similarly, a study by Lieu et al24 aimed at
identifying children at high risk of developing
asthma rather than identifying individuals
with asthma or high medical costs in a broader
age range. Their study employed proportionalhazard modeling and their findings regarding
predictors parallel the findings reported herein
in many respects: “having filled an oral steroid
prescription . . . having been hospitalized during the prior 6 months, and not having a
personal physician . . . were associated with
increased risk of future hospitalization. . . .
Classification trees identified previous hospitalization and ED visits, 6 or more -agonist inhalers (units) during the prior 6 months, and
three or more physicians prescribing asthma
medication during the prior 6 months as predictors.”
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The analyses reported herein entail a number of limitations:
• They focus solely on medical cost outcomes.
Other outcomes that might be examined include clinical outcomes and indicators of the
intensity/complexity of utilization (which
were actually employed herein as predictive
factors).
• The analyses included data from only one
DM program and on only three disease conditions.
• A single modeling technique was employed—neural networks.
An intriguing study finding is the relatively
low accuracy of the cardiac model (C  0.651)
relative to the total population model applied
to the cardiac cohort (C  0.726) and relative
to the other disease-specific models (asthma
model C  0.835 and diabetes model C 
0.786). One explanation may lie in the relatively
small size of the cardiac cohort (n  2,605) in
comparison with the diabetes (n  33,908) and
asthma (n  19,264) cohorts. Increasing enrollments in the cardiac cohorts of DM programs
will permit future testing of this interpretation.
Another possible explanation lies in the fact
that the cardiac cohort combines members with
two conditions, CHF and CAD, increasing the
complexity of the cohort and, presumably, reducing the potential for a single model to account simultaneously for the costs of members
with either condition.
There is clearly a need for further research to
address the questions of the comparative effectiveness of generic versus disease-specific
neural network models, and the variable effectiveness of models of different diseases. Incorporating a broader array of disease conditions—other chronic conditions such as cancer,
COPD, end stage renal disease, HIV/AIDS,
low back pain, and depression, as well as some
acute conditions such as high-risk pregnancy—
will also be of value.
Testing hypotheses about the variable effectiveness of disease-specific models should include incorporating information about disease
progression, and measuring specific disease
markers longitudinally over a longer time
span, preferably longer than 3 years. In general,
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as DM program enrollments and enrollment
longevity increase, such data should become
more widely available.

CONCLUSION
This study compared the effectiveness of a
total population neural network model predicting high medical costs with three disease
specific models. The most striking finding of
this research is that the effectiveness of predictive models varies by disease, ie, the diabetes
model appears to be more effective than the total population model, the asthma model appears roughly as effective, and the cardiac
model appears less effective than the total population model applied to the cardiac cohort. If
substantiated by further analyses, these results
suggest that DM program developers and administrators should test multiple approaches—
both generic and disease-specific—before finalizing and implementing predictive models
in DM programs. Additionally, the predictive
power of a model seems to be directly related
to its sample size. Thus, as in applications of
statistical analyses in general, DM program developers and administrators should be cautious
in applying predictive models to small samples.
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